# Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease

> **NCT01817972** · PHASE3 · UNKNOWN · sponsor: **Gastroenterology Research of America** · enrollment: 65 (estimated)

## Conditions studied

- Crohn's Disease

## Interventions

- **BIOLOGICAL:** Certolizumab pegol
- **DRUG:** Azathioprine

## Key facts

- **NCT ID:** NCT01817972
- **Lead sponsor:** Gastroenterology Research of America
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-03
- **Primary completion:** 2014-06
- **Final completion:** 2014-11
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2013-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01817972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01817972, "Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01817972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*